PAIP1, which is a component of the eukaryotic translation machinery, has been identified to interact with SUD
The GLP-1 RAs appear to modify atherosclerosis in the arteries, much like statin medications that treat cholesterol, and takes about a year or more to demonstrate measurable benefits on risk for cardiovascular events, whereas the SGLT2i medications seem to affect heart and kidney function more prominently and faster, with benefits evident very soon after starting the medication
Why Choose It Over Oral Supplements
doi: 10.1016/j.cca.2022.09.018 87 TomlinsonJ
To help people figure out who qualifies, what is involved and what to expect for first-time GLP-1 users, a pair of weight management specialists at MUSC Health sat down for this Q&A
The FDA and other regulatory agencies have conducted extensive reviews of safety data from clinical trials and post-marketing surveillance